BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Protalix Biotherapeutics, Inc. 

2 Snunit Street, Science Park
P.O. Box 455
Karmiel    21000  Israel
Phone: 972-4-988-9488 Fax: 972-4-988-9489


SEARCH JOBS

View Clinical Trials from BioPharm Insight









 Company News
Protalix Biotherapeutics, Inc. (PLX) Appoints Moshe Manor As President And CEO 9/29/2014 8:22:43 AM
Protalix Biotherapeutics, Inc. (PLX) Announces Conference Call To Discuss ELELYSO Pediatric Approval And Provide Updates On Additional Programs 8/29/2014 8:40:08 AM
Protalix Biotherapeutics, Inc. (PLX) Names Shlomo Yanai As Chairman Of The Board Of Directors 7/24/2014 10:09:41 AM
Protalix Biotherapeutics, Inc. (PLX) Announces New Data On ELELYSO™ (Taliglucerase Alfa) Presented At The European Working Group On Gaucher Disease 2014 11th Meeting 6/27/2014 8:53:11 AM
Protalix Biotherapeutics, Inc. (PLX) Announces New Data On ELELYSO™ (Taliglucerase Alfa) And Oral GCD To Be Presented At The European Working Group On Gaucher Disease 2014 11th Meeting 6/23/2014 7:36:02 AM
Protalix Biotherapeutics, Inc. (PLX) Initiates Phase 2 Study With PRX-112, An Orally-Administered Enzyme Replacement Therapy For The Treatment Of Gaucher Disease 6/18/2014 8:59:08 AM
Protalix Biotherapeutics, Inc. (PLX) CEO Will Retire This Year 6/13/2014 7:42:12 AM
Protalix Biotherapeutics, Inc. (PLX) Announces ELELYSO™ (Taliglucerase Alfa) Approved In Canada For The Treatment Of Gaucher Disease In Both Adult And Pediatric Patients 5/30/2014 7:00:49 AM
Protalix Biotherapeutics, Inc. (PLX) To Present At Two Upcoming Healthcare Conferences 5/28/2014 9:53:53 AM
Protalix Biotherapeutics, Inc. (PLX) Announces ELELYSO™ (Taliglucerase Alfa) Approved In Australia For The Treatment Of Gaucher Disease In Both Adult And Pediatric Patients 5/22/2014 9:32:26 AM
12345678910...